Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · SAMSRITA LABS LIMITED · 9 October 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
SAMSRITA LABS LIMITED
BSE: 539267
BSE: 539267
Healthcare › Healthcare › Healthcare Services › Healthcare Service Provider
SAMSRITA LABS LIMITED
StateQ1 FY27 filed
Last close · 8 Oct 2026₹11.18
Market cap₹0.0k cr
TTM P/E · P/B · EV/EBITDA3.3 · 2.16 · —
SAMSRITA LABS LIMITED is a Healthcare Services company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY19–FY26 (all audited; no estimate years)
| ₹ crore · consolidated | FY19 | FY20 | FY21 | FY26 |
|---|---|---|---|---|
| Revenue | 2 | 1 | 0 | 0 |
| EBITDA (ex other income) | (2) | (2) | (1) | (9) |
| margin % | (121.1) | (153.3) | (7209.2) | (48155.2) |
| Owners' profit | (2) | (0) | 0 | 0 |
| EPS, as reported (₹) | (3.66) | (1.31) | (0.43) | 3.99 |
| ROE % · ROCE % | (14.3) · (14.3) | (12.6) · (12.9) | (5.1) · (5.3) | (69.4) · (73.3) |
| Debt / equity (x) | 0.49 | 0.54 | 0.62 | 0.14 |
| Cash from operations | — | — | (0) | (5) |
| Capex | — | — | 0 | 0 |
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · SAMSRITA LABS LIMITED · 9 October 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q3 FY21 | Q4 FY21 | Q1 FY22 | Q2 FY22 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | (0) | (0) | (0) | (0) | (5) | (3) | (0) | (0) |
| Net profit | (0) | (0) | (0) | (0) | (5) | (3) | (0) | (0) |
| EPS (₹) | (0.12) | 0.09 | (0.03) | (0.02) | 2.00 | 1.29 | 0.06 | 0.08 |
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| DR. LAL PATH LABS LTD. | 31,807 | 45.8 | 12.52 | 37.0 | 20.1 | 24.8 | 11.8 | 35.0 |
| VIJAYA DIAGNOSTIC CEN LTD | 14,797 | 78.9 | 15.46 | 41.3 | 18.1 | 16.8 | — | 46.4 |
| METROPOLIS HEALTHCARE LTD | 10,885 | 22.5 | 7.14 | 26.0 | 12.5 | 14.4 | 10.5 | 25.8 |
| THYROCARE TECH LTD | 7,959 | 29.3 | 13.58 | 29.0 | 27.8 | 33.2 | 10.9 | 33.9 |
| NEPHROCARE HEALTH SERV L | 6,266 | 64.7 | 5.61 | 24.7 | 6.9 | 8.6 | — | 25.3 |
| KRSNAA DIAGNOSTICS LTD | 1,732 | 17.8 | 1.77 | 8.8 | 10.3 | 8.4 | — | 27.7 |
| SURAKSHA DIAGNOSTIC LTD | 1,641 | 45.8 | 6.74 | 16.6 | 12.9 | 11.5 | — | 36.0 |
| 3B BLACKBIO DX LTD. | 1,311 | 21.9 | 3.95 | 15.5 | 18.1 | 22.5 | (8.9) | 52.6 |
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 3.3 | 22.5 | 1 of 25 | 100% |
| P/B | 2.2 | 2.0 | 14 of 24 | 44% |
| ROCE | (73.3) | 6.1 | 27 of 29 | 7% |
| ROE | (69.4) | 6.0 | 23 of 24 | 4% |
| Debt / Equity | 0.1 | 0.1 | 15 of 23 | 36% |
| Profit growth | (696.2) | 22.0 | 24 of 25 | 4% |
| Market cap | 25 | 35 | 21 of 30 | 31% |
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · SAMSRITA LABS LIMITED · 9 October 2026Page 3 of 3
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 4 Oct 2026 · Newspaper publication of 1st EGM notice for FY 2026-27 | compliance | minimal | — | — |
| 3 Oct 2026 · Samsrita Labs announces 1st EGM for FY 2026-27 on October 26 | compliance | minimal | — | — |
| 3 Oct 2026 · EGM on 26 Oct for 3 RPTs worth up to Rs 26 Cr | board shareholder meetings | low | — | — |
| 28 Sept 2026 · Board approves Rs 1 Cr investment in S Labs Hygiene Care via CCPS | strategic transactions | medium | — | — |
| 25 Sept 2026 · Trading window closed from Oct 1 ahead of Q2 results | compliance | minimal | — | — |
| 14 Aug 2026 · Newspaper publication of Q1 FY27 financial results | compliance | minimal | — | — |
| 13 Aug 2026 · No deviation in use of preferential issue funds for Q1 FY27 | compliance | minimal | — | — |
| 13 Aug 2026 · Samsrita Labs Q1 FY27 results: nil revenue, wider standalone loss of INR 31.47 lakh | results | high | — | — |
| 13 Aug 2026 · Samsrita Labs Q1 FY27 loss widens to INR 31.47 lakh | results | high | — | — |
| 10 Aug 2026 · AGM: All 7 resolutions passed, share capital cut approved | board shareholder meetings | low | — | — |
Source: exchange announcements; reaction = close-to-close from the filing's session.
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in